Cancer Biomarkers Market to Witness High Demand Due to Increasing Cancer Cases

Cancer Biomarkers Market is forecasted to grow at 12.5% for 2019 to 2026 to an estimated value of USD 56.06 billion by 2026 with factors such as high investment cost and unfavorable reimbursement policies hampering the market growth.

Cancer biomarkers market has shown a significant adoption rate and preferences from Asia- Pacific with countries such as China, Japan and India. Rising cases of cancer, and growth in pharmaceutical companies in the region is expected to enhance the demand for cancer biomarkers.

Cancer Biomarkers Market Scenario

According to Data Bridge Market Research the cancer biomarkers market in developing regions is witnessing a high growth in terms of its adoption rate, due to increasing research on cancer biomarkers, technological advancement, and increasing usage of cancer biomarkers in drug discovery & development.

Now the question is which are the regions that cancer biomarkers market players should target? Data Bridge Market Research has forecasted market leaders to target Asia- Pacific and North American developing regions to help them in attaining better volume of revenue generation.

Cancer biomarkers market is becoming more competitive every year with protein biomarkers currently being the largest market type for the forecasted period of 2019 to 2026. Data Bridge Market Research’s new report highlights the major growth factors and opportunities in the cancer biomarkers market.

For more analysis on the cancer biomarkers market, request for a briefing with our analysts

Cancer Biomarkers Market Development

QIAGEN announced the launch of their therascreen PIK3CA RGQ PCR Kit in May 2019 after getting U.S. regulatory approval as a screening aid to help detect breast cancer patients who are eligible for PIQRAY treatment. It is also the first FDA approved assay to use plasma specimens as a liquid biopsy to guide treatment decisions in breast cancer.

Scope of the Cancer Biomarkers Market

Cancer biomarkers market on the basis of countries is segmented into U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa.

  • All country based analysis of the cancer biomarkers market is further analyzed based on maximum granularity into further segmentation. On the basis of type, the market is segmented into genetic biomarkers, protein biomarkers, and other cancer biomarkers. Based on cancer type, the market is segmented into breast cancer, lung cancer, prostate cancer, colorectal cancer, blood cancer, melanoma, ovarian cancer, liver cancer, stomach cancer, and other cancer types. Technology segment is divided into imaging technologies, omic technologies, cytogenetics-based tests, and immunoassays. On the basis of application, the market is segmented into drug discovery and development, personalized medicine, diagnostics, and others.
  • Cancer biomarkers are identifiable compounds that can be used as a biological tumor status indicator and can therefore be used to assess cancer diagnosis and prognosis levels. Some of the common types of cancer biomarkers are genetic biomarkers, protein biomarkers and other. They are widely used for detection of different kinds of cancers such as breast cancer, prostate cancer, lung cancer and others. Cancer biomarkers are widely used in applications such as drug delivery & development, personalized medicines, and other.

To know more about the study

Key Pointers Covered in the Cancer Biomarkers Market Industry Trends and Forecast to 2026

  • Market Size
  • Market New Sales Volumes
  • Market Replacement Sales Volumes
  • Market Installed Base
  • Market By Brands
  • Market Procedure Volumes
  • Market Product Price Analysis
  • Market Healthcare Outcomes
  • Market Cost of Care Analysis
  • Regulatory Framework and Changes
  • Prices and Reimbursement Analysis
  • Market Shares in Different Regions
  • Recent Developments for Market Competitors
  • Market Upcoming Applications
  • Market Innovators Study

Key Market Competitors Covered in the report

  • Abbott
  • DiagnoCure Inc
  • Affymetrix, Inc.
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Agilent Technologies Inc.
  • Quest Diagnostics Inc.
  • Merck & Co. Inc
  • Hologic, Inc
  • BD
  • GlaxoSmithKline plc
  • Novartis AG
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer, Inc.
  • Genomic Health, Inc.
  • bioMérieux SA
  • Astellas Pharma Inc.
  • Myriad Genetics
  • Epigenomics AG
  • Radient Pharmaceuticals

Above are the key players covered in the report, to know about more and exhaustive list of cancer biomarkers companies, contact us

Research Methodology: Global Cancer Biomarkers Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Related Reports

Browse in Healthcare Category Related Reports@